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Manso AM, Kang SM, Plotnikov SV, Thievessen I, Oh J, Beggs
HE, Ross RS. Cardiac fibroblasts require focal adhesion kinase for
normal proliferation and migration. Am J Physiol Heart Circ
Physiol 296: H627–H638, 2009. First published January 9, 2009;
doi:10.1152/ajpheart.00444.2008.—Migration and proliferation of
cardiac fibroblasts (CFs) play an important role in the myocardial
remodeling process. While many factors have been identified that
regulate CF growth and migration, less is known about the signal-
ing mechanisms involved in these processes. Here, we utilized
Cre-LoxP technology to obtain focal adhesion kinase (FAK)-
deficient adult mouse CFs and studied how FAK functioned in
modulating cell adhesion, proliferation, and migration of these
cells. Treatment of FAKflox/flox CFs with Ad/Cre virus caused over
70% reduction of FAK protein levels within a cell population.
FAK-deficient CFs showed no changes in focal adhesions, cell
morphology, or protein expression levels of vinculin, talin, or
paxillin; proline-rich tyrosine kinase 2 (Pyk2) expression and
activity were increased. Knockdown of FAK protein in CFs in-
creased PDGF-BB-induced proliferation, while it reduced PDGF-
BB-induced migration. Adhesion to fibronectin was not altered. To
distinguish between the function of FAK and Pyk2, FAK function
was inhibited via adenoviral-mediated overexpression of the nat-
ural FAK inhibitor FAK-related nonkinase (FRNK). Ad/FRNK had
no effect on Pyk2 expression, inhibited the PDGF-BB-induced
migration, but did not change the PDGF-BB-induced proliferation.
FAK deficiency had only modest effects on increasing PDGF-BB
activation of p38 and JNK MAPKs, with no alteration in the ERK
response vs. control cells. These results demonstrate that FAK is
required for the PDGF-BB-induced migratory response of adult
mouse CFs and suggest that FAK could play an essential role in the
wound-healing response that occurs in numerous cardiac patholo-
gies.
extracellular matrix; cytoskeleton; fibroblast
THE MAIN CELLULAR COMPONENTS of the heart include cardiac
myocytes, fibroblasts (CFs), endothelial cells, and smooth
muscle cells, with the majority being myocytes and fibroblasts.
Early studies in rat myocardium established that CFs com-
prised over 70% of the total number of cardiac cells (35, 63).
A more recent study established that the percentage of CFs in
the heart varies between species, being a higher number in
larger mammals and lower one in small mammals, such as
mice, in which CFs represent 30% of the total cells in the
heart (1). Under basal conditions, CFs contribute to extracel-
lular matrix (ECM) deposition and create a scaffold for cardiac
myocytes (2, 7). CFs are the main source of interstitial colla-
gen deposition in the normal and pathological heart. They
maintain ECM integrity and myocardial structure (11, 12).
In cardiovascular pathologies, such as hypertensive heart
disease, or ischemic and diabetic cardiomyopathy, fibroblasts
play an important role in the myocardial remodeling process
(61). With remodeling, hypertrophy of cardiac myocytes may
occur, but alterations in CF number, location, migration, and
proliferation can also be seen, leading to changes in the amount
and composition of the cardiac ECM. Excessive fibroblast
proliferation or increase in ECM content can lead to cardiac
fibrosis and increased myocardial stiffness and can cause
cardiac dysfunction (6). Furthermore, fibrosis can lead to
myocyte hypoxia, via perivascular scarring, or disrupt cell-cell
communication between myocytes, predisposing to arrhyth-
mias (46). Wound healing is an essential response after myo-
cardial infarction, and CFs are the main cellular component in
this process, migrating to the ischemic/peri-infarct area, in-
creasing synthesis of ECM proteins to replace necrotic myo-
cytes and then forming a scar (54, 61). Although cardiac
fibrosis is clearly associated with altered myocardial mechan-
ical performance, arrythmogenesis, and wound-healing re-
sponses, the function of CFs is still poorly understood, partic-
ularly compared with cardiac myocytes. Furthermore, while
substances such as growth factors and cytokines, or mechanical
stress (2, 7), have been shown to regulate CF growth and
migration, less is known about the signaling mechanisms
involved in these processes. Recent data suggest that interac-
tions between the ECM and integrins, and signaling events that
can arise from this interaction, are linked to these responses.
Integrins are heterodimeric cell-surface receptors that link the
ECM and the intracellular cytoskeleton. They serve both as
adhesive receptors and also direct intracellular events (45). In
binding of cells to ECM, focal adhesion (FAs) are formed, and
it is at these sites that a large number of proteins are recruited
to form a signaling complex.
FA kinase (FAK) is a nonreceptor protein-tyrosine kinase
that is one component of the FA complex that plays a major
role in signaling pathways initiated by integrins (33). FAK also
participates in signal transduction by G-protein-coupled recep-
tors, such as angiotensin II, and receptor tyrosine kinases, such
as the platelet-derived growth factor (PDGF) receptor (47). In
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various cell types, FAK may function as a convergence point
for signaling pathways triggered by integrins and other hu-
moral factors that are important in the regulation of cell
function (33).
Several recent studies have shown the important role for
FAK in the myocardium. For example, FAK expression and
activity were increased in the volume-overloaded myocardium
of patients with chronic mitral regurgitation (30). These
changes were mainly related to ones in CFs, as opposed to
myocytes, and they paralleled the increase in interstitial fibro-
sis seen in those patients. Thus FAK may contribute to the
fibrogenesis and structural abnormalities found in chronic vol-
ume overload of the heart (30). Moreover, small interfering
RNA knockdown of FAK expression in all cells within the
intact mouse heart allowed for reduced fibrosis in response to
chronic pressure overload (9). The pressure-loaded FAK-defi-
cient mice had improved heart function vs. control animals,
indicating the important role of fibrosis in the remodeling
process following pressure overload.
Despite this information, little data exist on the function of
FAK in adult CFs. In this study, we utilized a genetically
modified mouse model to obtain FAK-deficient adult CFs and
studied how FAK functioned in modulating cell adhesion,
proliferation, and migration of these cells. Our results demon-
strate that FAK is required in the migration of CFs as a
response to growth factors and suggest that FAK is involved in
the fibrotic process found in numerous cardiac pathologies.
MATERIALS AND METHODS
Antibodies and reagents. Mouse monoclonal antibodies and their
sources were as follows: vinculin and talin (clone hVIN and 8D4,
respectively) both from Sigma (St. Louis, MO); -smooth muscle
actin and GAPDH (clone 1A4 and 6C5), both from Santa Cruz
Biotechnologies (Santa Cruz, CA); and paxillin (clone 349, BD) from
Transduction Laboratories (San Jose, CA). Rabbit polyclonal antibod-
ies and their sources were as follows: FAK NH2 terminus (A-17),
FAK COOH terminus (C-20), desmin (H-76), and discoidin domain
receptor 2 (H-108) from Santa Cruz Biotechnologies; proline-rich
tyrosine kinase 2 (Pyk2) from Upstate/Millipore (Lake Placid, NY);
phospho-FAK Y397 and phospho-Pyk2 Y402 from Biosource Inter-
national (Camarrillo, CA); phospho-ERK and phospho-JNK from
Stressgene (Victoria, Canada); ERK1/2, p38, phospho-p38, and JNK
from Cell Signaling (Danvers, MA); 4,6-diamidino-2-phenylindole
dihydrochloride hydrate from Sigma (St. Louis, MO); and peroxidase-
conjugate AffiniPure Donkey anti-rabbit antibody from Jackson In-
munoResearch Laboratories (West Grove, PA). PDGF-BB was from
Biosource (Carlsbad, CA). Alexa Fluor 488 goat anti-mouse, Alexa
Fluor 568 goat anti-rabbit secondary antibodies, and phalloidin were
from Molecular Probes/Invitrogen (Carlsbad, CA).
Animals and preparation of adult mouse CFs. Construction of the
“floxed” FAK allele and production of genetically manipulated mice
was as published previously (3). These mice contain loxP sites
flanking exon 18, the kinase domain of the FAK gene. All animals
were housed in an American Association for Accreditation of
Laboratory Animal Care approved facility. All animal procedures
were reviewed and approved by the Institutional Animal Care and
Use Committee of the Veterans Administration San Diego Health-
care System. Primary adult mouse CFs were isolated from hearts of
homozygous “floxed” mice (termed FAKflox/flox) that were main-
tained in a C57BL/6 background, by using previously published
methods (59). The cells were grown to confluence at 37°C with 95%
air/5% CO2 in growth media [DMEM, 10% bovine calf serum (BCS)
(Hyclone), with the addition of 1% penicillin and 1% streptomycin
(PS) (Invitrogen)]. Cultures consistently showed fibroblast morphol-
ogy by microscopy and were positive for the discoidin domain
receptor 2, a marker for fibroblasts (34), and negative for desmin, a
smooth muscle cell marker (data not shown). All cells were used
between passages 2 and 4.
FAK-deficient CFs were created by adenoviral infection of the homozy-
gous floxed CFs derived from the FAK-flox mice (FAKflox/flox), with a
Cre-recombinase-expressing adenovirus (Ad/Cre) (Fig. 1A). CFs were
seeded at a concentration of 15  104 cells/well onto six-well plastic
plates in media containing DMEM, 10% BCS, and 1% PS. They were
rendered quiescent by their exposure to a defined serum-free DMEM
containing 0.1% bovine serum albumin (BSA)  1% PS for 24 h
before infection. For virus infection, CFs were incubated with adeno-
viruses Ad/Cre [200 multiplicity of infection (MOI)] or Ad/FRNK (25
MOI) for 96 and 48 h, respectively, as outlined in RESULTS. Stimula-
tion with PDGF-BB (10 ng/ml) was subsequently performed. Control
cells for all studies were created by infection of the FAKflox/flox
CFs with an adenovirus expressing -galactosidase (Ad/LacZ) at
matched MOIs and times. FAK gene excision and FAK protein
reduction were evaluated with polymerase chain reaction (3),
Western blot analysis, and immunofluorescent staining, respec-
tively.
Western blotting. At study termination, cells were washed in cold
PBS and scraped into lysis buffer (150 mM NaCO3, 1 mM EDTA,
pH  11) containing protease inhibitor cocktail (Roche Applied
Science, Indianapolis, IN). Equal amounts of protein lysate were
separated by SDS-PAGE using 9% polyacrylamide gels and trans-
ferred to a polyvinylidene difluoride membrane (Millipore, Bedford,
MA) by electroblotting. Membranes were blocked in PBS containing
Tween (0.1%), as well as 5% nonfat dry milk, and incubated with the
primary antibodies overnight at 4°C. Bound antibodies were visual-
ized by using secondary antibodies with horseradish peroxidase (Jack-
son ImmunoResearch Laboratories, West Grove, PA) and ECL re-
agents (Amersham Pharmacia Biosciences/GE Healthcare, Piscat-
away, NJ).
Fig. 1. Excision of the focal adhesion kinase (FAK) gene in FAKflox/flox
cardiac fibroblasts (CFs) by recombinant adenoviral Cre-recombinase virus
(Ad/Cre). A: diagrams of FAK floxed and excised alleles. Primers used for
identification of the unexcised and excised alleles are P1 and P2 (note:
diagrams are not drawn to scale). B: PCR fragments from intact or excised
floxed alleles were detected at 1.6 kb or 350 bp, respectively. The 350-bp
excised fragment was detected in FAKflox/flox CFs infected with Ad/Cre virus
at both 100 and 200 multiplicity of infection (MOI). No excised fragment was
detected in FAKflox/flox CFs infected with adenovirus expressing -galactosi-
dase (Ad/LacZ) (control) virus.
H628 FAK AND ADULT MOUSE CARDIAC FIBROBLASTS
AJP-Heart Circ Physiol • VOL 296 • MARCH 2009 • www.ajpheart.org
Immunofluorescent staining and FA analysis. Cellular immuno-
staining was performed as described previously (39). Briefly, 96 h
after infection, CFs were trypsinized and resuspended in DMEM
supplemented with 0.1% BSA and 1% PS and plated for 16 h on glass
coverslips coated with fibronectin (FN) at a concentration of 10
g/ml; fixed with 4% paraformaldehyde (PFA), permeabilized in
0.2% Triton X-100/PBS, and blocked with 3% BSA and 1.5% goat
serum in PBS. Primary antibodies [FAK (1:100), Pyk2 (1:100),
vinculin (1:400), and paxillin (1:200)] were applied overnight at 4°C.
After washing, secondary antibodies were applied [Alexa-488 or
Alexa-568 (1:500)] for 30 min at room temperature. Microscopic
analysis was performed using a Zeiss Standard microscope equipped
with epifluorescent optics and photographed using a Hamamatsu
cooled charge-coupled device camera (Hamamatsu Photonics, Bridge-
water, NJ). Quantitative analysis of FA size and shape was performed
using custom-built MatLab code (64). Briefly, images of vinculin
staining were processed with a median filter followed by subtraction
of local background, and interactive intensity threshold was applied to
create binary maps of FAs. Standard functions of Image Processing
toolbox (MathWorks, Natick, MA) were used to segment the maps
and to characterize each segment quantitatively. Measures of eccen-
tricity, size, and number were determined.
Cell adhesion assay. Cell adhesion assays were performed using
96-well cell culture plates. Plates were coated with FN at a concen-
tration of 10 g/ml for 2 h at 37°C and blocked with 3% BSA for 1 h
before plating cells. Cells were plated at a concentration of 2  104
cells/well and allowed to attach for 5, 15, 30, and 60 min at 37°C.
Following adhesion, nonadherent cells were removed, and adherent
cells were fixed with 4% PFA for 15 min at 4°C and stained with 0.5%
toloudine blue (Sigma) in 4% PFA for 5 min. After washing three
times with water, cells were solubilized with 1% SDS, and the relative
absorbance was measured at 595 nm on a microplate spectrophotom-
eter. Each assay was performed in triplicate, and the results averaged.
Cell proliferation assay. The proliferative activity of the cells was
determined by 5-bromo-2-deoxyuridine (BrdU) incorporation using a
cell proliferation ELISA kit (Calbiochem, San Diego, CA). A total of
5,000 cells were added to each well of 96-well microplate and
incubated for 24 h with PDGF-BB (10 ng/ml). Thereafter, 20 l of
BrdU (1:2,000) were added to each well and incubated for another 2 h.
BrdU incorporation was then evaluated by measuring the absorbance
at 450 nm, according to the manufacturer’s protocols. Each assay was
performed in triplicate, and the results averaged.
Cell migration assay. Migration of CFs was assessed using a
modified Boyden’s chamber method (QCM-FN; Chemicon Interna-
tional, Temecula, CA). Ninety-six hours after infection, CFs were
trypsinized and resuspended in DMEM supplemented with 0.1%
BSA. The cells were plated into upper chambers of Boyden chambers
(2  104 cells/chamber) and allowed to migrate for 3 h toward FN or
BSA-coated filters on the undersurface of the upper chamber.
PDGF-BB (10 ng/ml) was placed in the media of the lower chamber
as a chemoattractant. The Boyden chambers were then removed,
washed, and stained according to the manufacturer’s protocol. Sam-
ples were read at 540 nm on a microplate spectrophotometer. Each
assay was performed in triplicate, and the results averaged.
Wound-healing assay. Migration of CFs was assessed using a
wound-healing assay. CFs were seeded at a concentration of 2  105
cells/well onto 60-mm plastic plates in media containing DMEM,
10% BCS, and 1% PS. They were rendered quiescent by their
exposure to a defined serum-free DMEM containing 0.1% BSA 1%
PS for 24 h before infection. For virus infection, CFs were incubated
with Ad/Cre or Ad/LacZ (200 MOI) for 96 h. Ninety-six hours after
infection, CFs were “wounded” by manual scratching with a pipette
tip, washed with PBS, photographed in phase-contrast microscope (0
h point), and placed with PDGF-BB (20 ng/ml). Matched pairs were
photographed 48 h following PDGF stimulation.
Statistical analysis. All data are expressed as means 	 SE. Statis-
tical differences between experimental groups were determined by
using Student’s t-test, and values of P 
 0.05 were considered
significant.
RESULTS
Reduction of FAK expression alters expression of FA pro-
teins but does not change cell adhesion or morphology of CFs.
Since no means exist to specifically drive expression of the
Cre-recombinase in CFs in the intact heart, we produced
FAK-deficient CFs ex vivo. For this, we used Cre-LoxP tech-
nology to excise the FAK gene in isolated mouse CFs (3).
Cre-recombinase was delivered via adenoviral infection of CFs
cultured from homozygous FAK-flox mice (FAKflox/flox) (Fig.
1A). Cells infected with Ad/LacZ were used as controls
throughout the study. Efficiency of the recombinant adenoviral
infection of the CFs was first tested using varied MOIs of both
Ad/LacZ and Ad/Cre. Evaluation of the cells 48 h following
infection at 200 MOI showed that over 80% of the cells were
positive for either -galactosidase or Cre-recombinase expres-
sion, by colorimetric or immunofluorescent staining, respec-
tively (data not shown). No cytopathic effects of viral infection
were detected at this MOI. Therefore, an MOI of 200 was used
for the remainder of the study. We found that Ad/Cre infection
caused excision of the FAK gene in the FAKflox/flox CFs, as
analyzed by polymerase chain reaction (Fig. 1B) and averaged
over 70% reduction (69 	 7% reduction, P 
 0.001, n  5) of
FAK protein in Cre vs. LacZ-infected CFs (see Fig. 3, A and
B). Given this, the Ad/Cre-infected FAKflox/flox CFs were
referred to as FAK knockout (KO) cells, while the Ad/LacZ
infected FAKflox/flox CFs were used as control cells through the
remainder of the study.
Prior studies in cells other than CFs have shown that FAK
can modulate cell adhesion (31, 43), formation, and turnover of
FAs (19, 24, 37, 48, 52), and also alter cell morphology (52).
Therefore, we next examined the effects of FAK deficiency on
these properties of CFs. To study FA amount, area, and
distribution, we performed immunofluorescence analysis using
vinculin as a marker of FAs. FAK-deficient CFs did not show
differences in cell morphology. Vinculin immunostaining dis-
played a similar pattern of distribution in FAK-deficient and
control cells, revealing organized patches of FAs at the cellular
periphery (Fig. 2). No changes in number, area, or distribution
of FAs was detected between control and FAK-deficient cells
(data not shown). Paxillin, another marker of FAs, showed the
same distribution as vinculin (data not shown). Western blot-
ting was performed to quantitate FA-related protein levels and
indicated no change in vinculin, talin, or paxillin expression in
the FAK-deficient CFs (Fig. 3, A and B).
Pyk2 is a cytoplasmic tyrosine kinase that shares approxi-
mately a 45% amino acid sequence identity with FAK (33).
The expression of Pyk2 in various studies of FAK null cells has
been noted to be variable, depending on the cell type, the age
of the animal from which the cells were derived, or the culture
conditions. For example, Pyk2 expression was enhanced in
mouse embryonic fibroblasts (MEFs) from FAK null mice (29,
53), but was not changed in many of the cells or tissue samples
derived from conditional FAK KO mice (3, 4, 37). Thus to
determine whether Pyk2 levels or function might compensate
for FAK deficiency in adult CFs, we examined its expression,
activation, and localization in our FAK-deficient cells.
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By Western blotting, Pyk2 expression was increased in the
FAK-deficient CFs compared with control cells (51 	 16%,
P 
 0.05, n  5; Fig. 3, A and B). The Pyk2 species detected
in FAK-deficient cells migrated slightly slower compared with
the one detected in control cells. Phosphorylation of Pyk2 at
tyrosine 402 corresponds with its activation. Western blot
analyses showed that Pyk2 phosphorylation was also increased
in FAK-deficient cells (see Fig. 6, C and D).
Several studies have indicated that the subcellular distribu-
tion of FAK and Pyk2 are different. FAK is most commonly
localized in FAs, while Pyk2 is detected in the perinuclear area
(53). In adult CFs, FAK was localized at FAs and in the
nucleus (Fig. 2). Pyk2 showed the same distribution as FAK
(Fig. 2). Furthermore, localization of Pyk2 was similar in the
FAK-deficient cells compared with control cells.
Next, we investigated cellular adhesion of the adult mouse
CFs to ECM substrates, which are all expressed in the myo-
cardium: laminin, collagen I, and FN. Cell adhesion assays
were performed and indicated that wild-type CFs adhered best
to FN, regardless of binding time (data not shown). Therefore,
Fig. 2. Localization of FAK, proline-rich
tyrosine kinase 2 (Pyk2), and vinculin (Vin)
in control (Cntl) and FAK-deficient CFs.
FAK (green; A and D), actin (red; B and E),
and 4,6-diamidino-2-phenylindole (DAPI)
(blue; C and F) are shown in Cntl (A–C) and
FAK knockout (KO) cells (D–F). PYK2
(green; G and J), actin (red; H and K), and
DAPI (blue; I and L) are shown in Cntl (G–I)
and FAK KO cells (J–L). Vin (green; M and
P), actin (red; N and Q), and DAPI (blue; O
and R) are shown in Cntl (M–O) and FAK
KO cells (P–R). Immunofluorescent staining
of FAKflox/flox CFs infected with Ad/Cre
(FAK KO) or Ad/LacZ (Cntl) showed that
FAK protein was localized in focal adhe-
sions (FAs) and nucleus in Cntl cells (A and
C). The amount of FAK was reduced toward
background levels in Ad/Cre-infected cells
compared with Ad/LacZ-infected cells (D
and F). Pyk2 showed a similar distribution to
FAK, localizing in FAs and nucleus in Cntl
cells (G and I), and no changes in Pyk2
localization were seen between Cntl and
FAK KO cells (G and I; J and L). Vin, a
marker of FAs, showed a similar distribution
in both Cntl and FAK KO cells (M and O; P
and R). Phalloidin (red) was used to mark
F-actin, and DAPI (blue) labeled nuclei.
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we used FN as a substrate for comparative adhesion of wild-
type and FAK-deficient CFs. The FAK-deficient CFs and
control-infected cells exhibited no significant differences in
adhesion to FN, independent of binding time (5, 15, 30, and 60
min) (Fig. 3C). These results show that reduced FAK expres-
sion does not affect 1) the formation and distribution of FAs;
2) the morphology; or 3) the adhesive capability of mouse adult
CFs to FN, in our culture system. Yet Pyk2 becomes upregu-
lated and activated in CFs deficient in FAK, possibly as a
compensatory mechanism.
Proliferation is increased and motility is inhibited in FAK-
deficient CFs. FAK has been shown to both positively and
negatively influence cell proliferation in a variety of cell types
(10, 41). Therefore, we next investigated whether FAK defi-
ciency affected cell proliferation in adult mouse CFs. We used
PDGF to provoke cell proliferation, since it has been shown to
be a major determinant of this process in a majority of
fibroblasts (44) and is a particularly strong mitogen for adult
mouse CFs (42). FAK-deficient CFs stimulated with
PDGF-BB displayed a significant increase in cell proliferation
compared with control cells (FAK KO  PDGF-BB: 213 	
13%, control  PDGF-BB: 132 	 12%, P 
 0.0001, n  5;
Fig. 4A).
FAK is also known to regulate cell migration through its
promotion of stable lamellipodia formation, necessary for di-
rectional locomotion, and facilitation of trailing-edge FA re-
lease or retraction (4, 23, 37, 48, 58, 60). FAK links both
ECM/integrin and growth factor stimulation to intracellular
signals promoting cell migration. PDGF-BB is able to stimu-
late cell migration of CFs. Therefore, we next investigated
whether FAK deficiency affects PDGF-BB-stimulated CF cell
migration. Migration was first examined using a modified
Boyden chamber assay. Migratory activity of the FAK-defi-
cient CFs was reduced compared with control CFs (Ad/Cre 
PDGF-BB: 192 	 16%, Ad/LacZ  PDGF-BB: 356 	 25%,
P 
 0.001, n  3; Fig. 4B). To further examine migration, we
also performed companion studies using an in vitro wound-
healing assay. When control cells in a confluent monolayer
were analyzed for their ability to repopulate the wounded area,
they were observed to migrate across the midportion of the
open space within 48 h after wounding. In contrast, FAK-
deficient CFs migrated slower than control cells (Fig. 4C).
These results indicate that FAK deficiency disrupts PDGF-BB-
stimulated migration of adult mouse CFs.
FRNK inhibits CF motility but not proliferation. Since Pyk2
has also been shown to be involved in cell proliferation and
migration (17, 40) and was increased in FAK-deficient CFs, we
sought to define if the increase in cell proliferation seen in
FAK-deficient CFs was directly related to FAK deficiency, or
if it might also be due to increases in Pyk2. For this purpose,
we utilized an alternative method to inhibit FAK function using
FAK-related nonkinase (FRNK). FRNK is a truncated product
of FAK that displaces FAK from the FA and, therefore, acts as
an inhibitor of endogenous FAK function. FRNK was overex-
pressed in normal mouse CFs by infection with a FRNK
recombinant adenovirus (39). CFs infected with the Ad/FRNK
did not exhibit alterations in FAK expression. Furthermore,
Pyk2 expression levels were similar in the Ad/FRNK and
control infected cells (Fig. 5, A and B). CFs treated with
Ad/FRNK and also stimulated with PDGF-BB were found to
proliferate at the same rate as control cells stimulated with
PDGF-BB [Ad/FRNK  PDGF-BB: 116 	 10%, control
(Ad/LacZ)  PDGF-BB: 125 	 6%, n  4; Fig. 5C]. Thus
these data suggest that the increased proliferation of CFs
deficient in FAK was, at least in part, related to concomitant
Fig. 3. Reduction of FAK expression alters expression of FA proteins but does
not change adhesion to fibronectin of adult CFs. A: lysates from FAKflox/flox
CFs infected with Ad/Cre or Ad/LacZ (200 MOI) for 96 h were analyzed by
Western blotting for FAK and other key FA proteins: Vin, paxillin, Pyk2, and
talin. GAPDH was used as a loading Cntl. Blots are representative of 5
independent experiments. B: densitometric analysis was performed on Western
blots by normalizing FAK, Vin, talin, paxillin, and Pyk2 expression to
simultaneously measured GAPDH. CFs infected with Ad/Cre showed a 70%
reduction of FAK protein expression (**P 
 0.001, n  5) and 52% increase
of Pyk2 (*P 
 0.05, n  5) compared with Cntl infected CFs. No other
significant alterations in protein expression were found. Data represent mean
values 	 SE. C: adhesion of FAK-deficient CFs (Ad/Cre) to fibronectin was
not different from that of Cntl cells when evaluated at 10, 30, and 60 min
following plating on a fibronectin matrix.
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upregulation of Pyk2. In contrast to the effects on proliferation,
PDGF-BB-stimulated CFs treated with Ad/FRNK migrated
less than control cells [Ad/FRNK  PDGF-BB: 102 	 7%,
control (Ad/LacZ)  PDGF-BB: 140 	 7%, P 
 0.05, n  3;
Fig. 5D]. These results indicated that FAK deficiency and not
Pyk2 upregulation caused the migration defects seen in FAK-
deficient adult mouse CFs.
PDGF-BB-mediated signaling in FAK-deficient CF. Phos-
phorylation of FAK may occur as a result of diverse cellular
stimuli (38) and provoke cellular events, such as migration and
proliferation. Whether PDGF-BB causes activation of FAK
appears to vary by cell type, with some cells showing robust
phosphorylation of FAK on various residues, while other cell
types showing no significant change (20, 51, 55). Therefore, we
assessed if FAK phosphorylation would occur in mouse CF stimu-
lated with PDGF-BB for 5–30 min. As shown in Fig. 6, A and B,
FAK was highly phosphorylated under basal conditions, and
stimulation with PDGF-BB did not cause significant changes in
the phosphorylation of FAK at either Tyr 397, its autophos-
phorylation site, or Tyr 576 (data not shown) in control-
infected CFs (Fig. 6, A and B). With FAK gene excision
effected by Cre-recombinase, residual FAK protein was seen to
be highly phosphorylated at Tyr 397 (data not shown).
Since we noted basal changes in Pyk2 in the FAK KO cells,
we also assessed Pyk2 activation in response to PDGF-BB
stimulation. As show in Fig. 6C, Pyk2 phosphorylation at Tyr
402, the autophosphorylation site akin to Tyr 397 of FAK, was
increased in response to PDGF-BB in control CF. Moreover,
PDGF-BB mediated a greater increase in Pyk2 activation in the
FAK KO CFs, compared with control cells.
Given our finding that FRNK may modify the migration
of the FAK-deficient CFs, as well as prior work that has
shown how FRNK overexpression could inhibit phosphor-
ylation of both FAK and Pyk2 (14), we next tested how
FRNK might modify the PDGF-BB-mediated Pyk2 activa-
tion in our cells. As shown in Fig. 7, FRNK overexpression
did not change baseline phosphorylation levels of Pyk2, but
inhibited PDGF-BB induction of Pyk2 phosphorylation.
Mitogen-activated protein kinase (MAPK) signaling path-
ways have been linked to cell proliferation and migration in
various cell types, including CFs (18, 28, 32). Furthermore,
previous studies have demonstrated that FAK was involved in
MAPK activation, which occurs in response to factors such as
PDGF-BB (15, 55, 57). Therefore, to further address the
molecular mechanisms through which reduced FAK expres-
sion inhibited PDGF-BB-stimulated cell motility in CFs, we
investigated activation of a series of MAPKs in the FAK-
deficient CFs. Adult control and FAK KO CFs were stimulated
with PDGF-BB for time points between 5 and 30 min. Whole
cell lysates were prepared and analyzed for MAPK activities.
The kinetics and activities of PDGF-BB-stimulated ERK42/44
were not altered in the FAK-deficient cells compared with control
cells, and JNK and p38 MAPKs were only moderately altered in
FAK-deficient cells compared with control cells (Fig. 8). These
Fig. 4. FAK-deficient CFs have reduced migration and increased proliferation
in response to platelet-derived growth factor (PDGF)-BB. A: cell proliferation
was increased in FAK-deficient CFs, as determined by 5-bromo-2-deoxyuri-
dine (BrdU) incorporation. FAK KO or Cntl CFs were incubated for 24 h with
PDGF-BB (10 ng/ml), with the last 2 h in the presence of BrdU. FAK KO CFs
showed an increase in proliferation compared with Cntl CFs (#P 
 0.001 vs.
Cntl  PDGF BB; *P 
 0.001 vs. No PDGF BB, n  5). B: migration of
FAK-deficient CFs was reduced as quantified using a Boyden chamber migra-
tion assay. FAK KO CFs had reduced migration toward 10 ng/ml PDGF-BB
in a Boyden chamber assay compared with Cntl CFs when evaluated over 3 h
(#P 
 0.001 vs. Ad/LacZ  PDGF-BB; *P 
 0.001 vs. No PDGF-BB; n 
3). Data represent mean values 	 SE. C: wound assays show reduced
migration of FAK KO CFs compared with Cntl cells when stimulated with 20
ng/ml of PDGF-BB. Matched pairs were photographed 48 h following PDGF
stimulation.
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results indicate that MAPK activation is preserved in adherent,
FAK-deficient CFs stimulated with PDGF-BB.
DISCUSSION
Proliferation and migration of CFs are key events in cardiac
remodeling. Excessive proliferation and migration, together
with matrix production and deposition, can lead to fibrosis,
which increases myocardial stiffness and may lead to diastolic
and potentially systolic dysfunction. Many factors have been
identified that regulate CF growth and migration, such as
growth factors, cytokines, or mechanical stress (2, 7). While it
is clear that the responses to these factors can be dependent on
ECM/integrin interactions, the specific role of FAK, one of the
main kinases that transmits integrin signaling, is not fully
understood.
In this study, we generated FAK-deficient cells from fully
mature CFs by Cre-mediated excision of a floxed-FAK allele
and showed that these cells had no changes in FA or gross
cellular morphology, nor expression levels of the FA and
adapter proteins vinculin, talin, or paxillin. Paralleling the
reduction in FAK, we observed an increase in Pyk2 expression
and activity, likely as a compensatory mechanism for loss of
FAK. With FAK reduction, the adult CFs still had adhesive
properties equivalent to control cells, but showed decreased
migration and increased proliferation in response to PDGF-BB.
Companion studies with FRNK as an inhibitor of FAK dem-
onstrated that FAK plays a key role in PDGF-BB-induced
migration in mouse adult CFs. Finally, while PDGF-BB caused
an increase of Pyk2 phosphorylation in the FAK-deficient CF,
there was no change in ERK activation, and only minimal
changes in activity of p38 and JNK.
Cell adhesion to ECM is essential for processes such as cell
cycle progression and to protect cells from apoptosis (21). In
migratory cells like fibroblasts, motility occurs by the forma-
Fig. 5. FAK-related nonkinase (FRNK) expression inhibits PDGF-BB-stimulated migration in CFs but does not change proliferation. A and B: lysates from CFs
infected with Ad/FRNK or Ad/LacZ (Cntl) (25 MOI, each) for 48 h were analyzed by Western blotting (A) with antibodies to FAK, Pyk2, and tubulin. The blots
are representative of 3 independent experiments. B: densitometric analysis was performed by normalizing FAK and Pyk2 expression to simultaneously measured
tubulin. Data represent mean values 	 SE. C: cell proliferation of CFs was not altered by FRNK as determined by BrdU incorporation. CFs infected with
Ad/FRNK or Ad/LacZ (Cntl) were incubated for 24 h with 10 ng/ml PDGF-BB with the last 2 h in the presence of BrdU. CFs infected with Ad/FRNK did not
show any difference in proliferation compared with Cntl CFs (*P
 0.001 vs. No PDGF-BB, n 4). D: FRNK causes reduced migration of CFs when quantified
using a Boyden chamber migration assay. CFs infected with FRNK (Ad/FRNK) or LacZ (Cntl) were allowed to migrate for 3 h toward 10 ng/ml PDGF-BB.
Increased expression of FRNK in CFs caused a reduction in migration compared with Cntl CFs (#P 
 0.01 vs. Cntl  PDGF-BB, *P 
 0.01 vs. No PDGF BB,
P 
 0.05 vs. Cntl, n  3). Data represent mean values 	 SE.
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tion of new FAs at the leading edge of the cell. In our study,
FAK-deficient CFs exhibited no significant alteration in adhe-
sion to FN. Studies of FAK null embryonic stem cells, as well
as keratinocytes, have similarly shown no changes in surface
levels of integrins and adhesion to several ECM substrates (22,
48). Thus it appears that FAK is not necessary for normal
adhesion of adult mouse CFs.
Several publications that focus on the role of FAK in FA
assembly and turnover have utilized undifferentiated embry-
onic cells such as MEFs. Early studies found that these cells
have an increase in FA size and number, as well as reduced
migration, and linked these changes to a decrease in FA
turnover (35). More recently, Lim and colleagues (29) demon-
strated that these alterations in FAs were caused by upregula-
tion of Pyk2 in the FAK-deficient cells, as reduction of Pyk2
expression in the FAK/ MEFs resulted in normalization of
both the number and size of FAs. Still, additional studies
underscore the necessity to research the role of FAK in differ-
Fig. 6. FAK and Pyk2 activation in response to PDGF-BB. FAK KO or Cntl CFs were treated with 10 ng/ml PDGF-BB for various times as indicated. A: total
and Tyr 397 phosphorylated FAK (p-FAK) protein were analyzed by Western blotting and showed no increase in phosphorylation in Cntl cells after PDGF-BB
treatment. B: densitometric analysis was performed on Western blots by normalizing p-FAK (Tyr 397) to total FAK (n  3). Data represent mean values 	 SE.
C: total and Tyr 402 phosphorylated Pyk2 (p-Pyk2) protein were analyzed by Western blotting and showed an increase in phosphorylation at Tyr 402 in Cntl
and FAK KO cells in response to PDGF-BB. D: densitometric analysis was performed on Western blots by normalizing p-Pyk2 (Tyr 402) to total Pyk2 [*P 

0.05 vs. Cntl (No PDGF-BB), P 
 0.01 vs. FAK KO (No PDGF-BB), #P 
 0.01 vs. Cntl PDGF-BB (30 min), n  7]. Data represent mean values 	 SE.
Fig. 7. Pyk2 activation in response to PDGF-BB in FRNK-treated cells. Ad/FRNK or LacZ (Cntl) CFs were treated with 10 ng/ml PDGF-BB for 30 min. A: total
and Tyr 402 p-Pyk2 protein were analyzed by Western blotting and showed no increase in phosphorylation in Ad/FRNK-treated cells after PDGF-BB treatment.
B: densitometric analysis was performed on Western blots by normalizing p-Pyk2 (Tyr 402) to total Pyk2 (n  5). P 
 0.05 vs. Cntl (No PDGF-BB). Data
represent mean values 	 SE.
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entiated cell types, as we have done here using adult CFs. For
example, FAK-deficient keratinocytes had a decreased rate of
FA disassembly leading to abnormally large FAs (48). In
endothelial and intestinal epithelial cells, FAK deficiency
caused a decrease in the number of FAs (4, 24), perhaps due to
a decrease in FA assembly, while FAK null macrophages
showed reduced assembly and disassembly rates of FAs, lead-
ing to preservation of FA number and size (37). In the present
study, no change in FA number or distribution was found.
Likewise, protein levels of the FA proteins vinculin, talin, and
paxillin were not altered, suggesting that the assembly and
disassembly rates of FA were not significantly altered in
FAK-deficient cells derived from adult CFs.
FAK-deficient MEFs have an altered and rounded epithelial-
like morphology (3, 37, 48, 58, 62). Recent work demonstrates
that this morphological change appears to be caused by the
increased levels of Pyk2 found in the FAK-deficient MEF,
leading in turn to an increase in p190RhoGEF expression and
aberrant RhoA activation (29). Indeed, when we made adult
mouse CFs deficient in FAK, upregulation and activation of
Pyk2 occurred, but the CFs did not show any change in cell
morphology compared with control cells. These differences
indicate that the concomitant FAK deficiency and Pyk2 up-
regulation likely have unique effects in differentiated fibro-
blasts derived from adult tissue, as we studied here, vs. an
immature embryonic source. Furthermore, these data are in line
with other studies that showed that fibroblasts from different
organs display distinct and characteristic transcriptional pat-
terns and should be analyzed as distinct cell types, despite all
being of a “fibroblast” lineage (8, 50). Furthermore, the ex-
Fig. 8. Activation of MAPKs by PDGF-BB in FAK-deficient CFs. FAK KO or Cntl CFs were treated with 10 ng/ml PDGF-BB for various times as indicated.
Activated and total ERK1/2 (A), JNK (B), and p-38 (C) were analyzed by Western blotting and showed only a trend toward increased phosphorylation of JNK
and p38 in the FAK-deficient CFs compared with Cntl cells. Overall, no statistically significant differences in MAPK activation was noted in the KO cells. The
blots are representative of at least three independent experiments.
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pression and subcellular localization of Pyk2 appear distinct in
CFs in contrast to MEFs. MEFs have minimal Pyk2 expres-
sion, while wild-type CFs display significant Pyk2 protein
levels. On the other hand, MEFs display Pyk2 in a perinuclear
pattern (53), while CFs show Pyk2 to be localized to FA and
nucleus. This FA localization of Pyk2 in CFs has been also
shown in other cell types, such as keratinocytes (48), smooth
muscle cells (5), and osteoblasts (25). These data suggest
unique roles of Pyk2, depending on cell type, and also indicate
that FAK and Pyk2 expression are finely balanced. Thus when
FAK is decreased, Pyk2 may be increased and/or activated.
Finally, our data showed not only how the FAK-deficient CFs
exhibited increased Pyk2 protein levels as well as an activa-
tion, but that the species of Pyk2 that increased was of a higher
molecular weight than that detected in control cells. Pyk2 of a
higher molecular weight was also detected in fibroblasts de-
rived from embryos of FAK KO mice (53). This may result
from an increase in the phosphorylation status of Pyk2 or, as
Sieg et al. suggest (53), to a change in the protein variant/
isoform of Pyk2, which becomes expressed in these cells.
Further studies will be necessary to answer this question.
Role of FAK in proliferation. Many studies support the
important role that FAK plays in regulating cell cycle progres-
sion by integrating signals from integrins and growth factor
receptors (38). Previous studies have shown that inhibition of
FAK expression results in decreased cell proliferation. Gilmore
and Romer (13) used human umbilical vein endothelial cells
and 3T3 cells to demonstrate that the displacement of the
endogenous FAK by overexpression of a construct containing
a FAK FA targeting sequence, but not the kinase domain,
decreased cell proliferation. Zhao et al. (65) also demonstrated
in 3T3 cells that inhibition of FAK provoked a decrease of
cyclin D1 expression, a regulator of cell progression through
the G1 to S phase. Subsequent studies in smooth muscle,
endothelial, and hepatic cells (43, 56) support the role of FAK
as a positive regulator of cell proliferation. Our results showed
that FAK protein depletion in CFs increased PDGF-BB-in-
duced proliferation. The CFs were found to have upregulation
and activation of Pyk2, in parallel with the reduction of FAK.
Thus we carried out companion studies to inhibit FAK activity
by overexpression of FRNK. In this case, Pyk2 levels were not
changed, and cell proliferation was normal. Thus it is likely
that the proliferative changes of FAK null CFs may be at least
in part linked to the changes in Pyk2.
In agreement with this result was a recent study that affected
upregulation of Pyk2 in FAK KO MEFs, leading to prolifera-
tion through the upregulation of p190RhoGEF expression (29).
Role of FAK in migration. FAK has been shown to play a
key role in cell motility in a range of cell types, including
embryonic fibroblasts, smooth muscle cells, endothelial cells,
epithelial cells, 3T3 cells, adenocarcinoma cells, macrophages,
and keratinocytes (13, 15, 16, 24, 29, 37, 48, 49, 51, 56). In
these cells, the function of FAK was investigated by several
methods, including use of inhibitors, such as FRNK or FAK
truncated products, or by producing FAK deficiency invoked
by global KO, small interfering RNA, or a Cre/LoxP system.
These studies showed that inhibition of FAK function or
expression lead to a decrease in the migratory responses to
growth factors like PDGF-BB and VEGF, G-protein-coupled
receptor agonists like lysophosphatidic acid, and induction by
ECM proteins such as FN. In contrast, a study using HeLa cells
plated on a collagen substrate showed that cell migration was
enhanced by inhibition of FAK expression or activity through
the dissolution of N-cadherin-mediated cell-cell contacts (62).
Our studies in adult mouse CFs are in agreement with the
majority of studies, in that FAK depletion or inhibition de-
creased migration. As PDGF-BB increased migration of the
FAK-deficient CFs, this suggests that a component of PDGF-
BB-mediated migration is independent of FAK activity. It is
possible that this residual migratory effect of PDGF-BB could
be provoked through Pyk2, as several studies in different cells
types, such as macrophages (36) and endothelial cells (27),
have linked Pyk2 with cell migration. In agreement with this
hypothesis is that small hairpin RNA-mediated inhibition of
Pyk2 in FAK KO MEFs caused reduction of residual motility
on FN. Still, the upregulation of Pyk2 in the FAK-deficient CF
background was unable to completely compensate/rescue the
motility defects of these cells, underscoring the essential role
of FAK in migration of CFs. Another possibility that we cannot
rule out is that residual FAK could still be functional and
responsible for the residual migration after PDGF-BB treat-
ment.
FAK is known to regulate cell migration through its promo-
tion of stable lamellipodia formation, necessary for directional
locomotion, and facilitation of trailing-edge FA release or
retraction (4, 15, 23, 37, 48, 58, 60). Additional work will be
needed to elucidate if FAK is acting through these mechanisms
in mouse CFs.
PDGF-BB-mediated signaling in FAK-deficient CF. In the
CFs studied here, FAK was highly phosphorylated at Tyr 397
in basal conditions where the cells were attached, and subse-
quent PDGF-BB stimulation did not cause significant changes
in phosphorylation at either Tyr 397 or Tyr 576 (data not
shown). Prior work in agreement with our finding has showed
that PDGF-BB does not increase Tyr 397 phosphorylation, but
produced alteration in FAK localization, as it became associ-
ated with an activated PDGF-receptor complex as cell migra-
tion was induced by PDGF-BB (51). Although many studies
have shown that phosphorylation of FAK at Tyr 397 increases
upon cell stimulation with a variety of factors, a growing
number has also shown that the basal phosphorylation levels of
this tyrosine is high in cells attached to a substratum, and that
subsequent treatment with stimuli does not enhance its phos-
phorylation further (16, 51). In contrast, the residual FAK
protein assayed in pools of the FAK-deficient CFs was highly
phosphorylated at Tyr 397. This was previously reported in
human carcinoma cells treated with antisense oligonucleotides
to reduced FAK (16). The residual FAK protein in cells within
a group of cells may still be functional and thus contribute to
PDGF-BB signaling involved in proliferation and migration.
As opposed to FAK, we found that Pyk2 became phosphor-
ylated at Tyr 402 in response to PDGF-BB stimulation, and
that this phosphorylation was higher in FAK-deficient cells.
This further underscores the compensatory role of Pyk2 in
FAK-deficient cells and also suggests that Pyk2 could be
playing a role in the increase of proliferation shown by FAK-
deficient cells after PDGF-BB treatment.
MAPK signaling in FAK-deficient cells. MAPKs are a fam-
ily of serine/threonine kinases that are well known to play an
important role in cell proliferation and migration (18). Previous
studies have demonstrated that FAK was involved in MAPK
activation, which occurs in response to factors such as
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PDGF-BB (15, 55, 57). Our results show that the kinetics of
PDGF-BB-stimulated ERK1/2, JNK, and p38 activities were
not significantly altered in FAK-deficient cells compared with
control cells. In contrast with our results, previous studies in
p53-transformed FAK null MEFs show a reduction in the
extent and duration of integrin and growth factor-stimulated
ERK, as well as JNK activation (26). In others studies with
vascular smooth muscle cells, FRNK overexpression caused
inhibition of the duration and extent of ERK activation by
PDGF-BB. Furthermore, these investigators directly showed
that ERK activity was required for PDGF-BB-induced migra-
tion (15). In other studies with vascular smooth muscle cells,
FRNK expression inhibited PDGF-BB activation of JNK (55).
In carcinoma cells, FRNK expression blocked ERK2 and JNK
activation, as well as the ERK-dependent, EGF-stimulated
migration (16). Differences between our own data and this
prior work display the distinct functional role that FAK has in
specific cell types.
Conclusion. In conclusion, we used Cre LoxP technology to
excise the FAK gene specifically in adult CFs. With this, we
showed that FAK played critical roles in PDGF-BB-induced
migration. FAK deficiency increased expression of Pyk2 but
did not significantly change activities of ERK, JNK, or p38
MAPKs. Altered migration of CFs may occur in a variety of
heart diseases, such as that found in the remodeling response
following myocardial infarction. Improved knowledge of the
mechanisms involved in this process may lead to new thera-
peutic targets, which could mitigate detrimental cardiac fibro-
sis. Further studies using in vivo models will be necessary to
directly assess the role of CF FAK in a range of myocardial
disease processes.
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